Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536692 · ClinicalTrials.gov registry record · Phase 2
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
A Phase 2 study, sponsored by CoMentis.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00536692: Completed Phase 2 study, sponsored by CoMentis.
NCT00536692 is a Phase 2 study that has completed, run by CoMentis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00536692, a Phase 2 study, has completed, sponsored by CoMentis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
Interventions
- DRUG mecamylamine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-09 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536692
The ClinicalTrials.gov registry entry for NCT00536692 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is CoMentis, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mecamylamine is the first listed.
NCT00536692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00536692 about?
NCT00536692 is a clinical study titled "Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)". This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
What is the current status of trial NCT00536692?
This trial is currently completed. It is a Phase 2 study. The study started on 2007-09. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00536692?
The interventions under investigation include: mecamylamine (DRUG).
Who is sponsoring clinical trial NCT00536692?
This trial is sponsored by CoMentis, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.